Monogram Orthopaedics Q2 2025 Earnings Report

Monogram Orthopaedics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.11
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Monogram Orthopaedics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Monogram Orthopaedics Announcement Details

• Quarter: Q2 2025
• Date: 8/13/2025
• Time: Before Market Opens
• Conference Call Date: Friday, August 8, 2025
• Conference Call Time: 9:30AM ET

Monogram Orthopaedics (NASDAQ:MGRM), Inc. (NASDAQ: MGRM) is a medical device company focused on the design, manufacture and commercialization of patient-specific implants and instrumentation for corrective osteotomy procedures. Leveraging advanced 3D imaging and additive manufacturing technologies, the company aims to improve surgical precision and patient outcomes in the treatment of knee osteoarthritis and related deformities. By tailoring implants and surgical guides to individual anatomy, Monogram seeks to reduce intra-operative variability and accelerate post-operative recovery.

The company’s core offerings include personalized angular stable plates and cutting guides for high tibial osteotomy (HTO), distal femoral osteotomy (DFO) and tibial tubercle osteotomy (TTO). Each implant and instrument is planned using proprietary software that converts CT or MRI scans into a detailed surgical blueprint, allowing surgeons to execute pre-planned corrections with high accuracy. Monogram’s additively manufactured implants feature optimized geometry and variable stiffness zones designed to support natural bone healing under load.

Founded in 2014 and headquartered in Santa Clara, California, Monogram Orthopaedics has established commercial operations across the United States and Europe. The company has obtained FDA clearance for its osteotomy system in the U.S. and secured CE marking for its products in the European Union. Monogram collaborates closely with leading orthopedic centers and imaging facilities to streamline patient workflow and expand clinical adoption of its technology platform.

Under the leadership of Chief Executive Officer Nathan Engler, a veteran of the orthopedic industry, Monogram continues to invest in research and development aimed at broadening its anatomical applications and enhancing its digital planning tools. As the company scales its manufacturing capabilities and builds strategic partnerships, it seeks to address unmet needs in deformity correction and to set new standards in personalized orthopedic care.